Skip to main content
Neogen Chemicals Limited logo

Neogen Chemicals Limited — Investor Relations & Filings

Ticker · NEOGEN ISIN · INE136S01016 LEI · 335800PFY9B77Z2GOK22 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2026-01-02 Director's Dealing
Country IN India
Listing BSE.NS NEOGEN

About Neogen Chemicals Limited

https://neogenchem.com/

Neogen Chemicals Limited specializes in the development and large-scale manufacturing of bromine-based and lithium-based specialty chemicals. The product portfolio includes a diverse range of bromine derivatives, lithium salts, Grignard reagents, and advanced intermediates. These products serve critical roles in pharmaceutical, agrochemical, and engineering applications. The company has expanded its operations into the energy storage market, focusing on the production of electrolytes and lithium salts for lithium-ion batteries. With a strong emphasis on research and development, the firm provides custom synthesis and contract manufacturing services to global innovators. Manufacturing capabilities are supported by multi-product facilities designed to meet stringent quality standards for complex chemical processes and high-purity requirements.

Recent filings

Filing Released Lang Actions
General Updates
Director's Dealing Classification · 88% confidence The document is a filing under SEBI (Prohibition of Insider Trading) Regulations 2015, disclosing personal share transactions by Beena Haridas Kanani (a promoter group member and relative of a director), including sale of equity shares by off-market gift. This is clearly an insider dealing disclosure rather than a corporate financial report or announcement, matching the definition of Director’s Dealing (Code: DIRS).
2026-01-02 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification about the closure of the trading window in compliance with insider trading regulations ahead of the announcement of quarterly financial results. It does not contain any financial data or results itself, nor does it present a report. The document is short (2303 characters) and serves as an announcement related to the timing of financial disclosures and trading restrictions. Therefore, it is not an Interim/Quarterly Report (IR) or Earnings Release (ER), but rather a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2025-12-27 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated November 28, 2025, announcing a joint venture agreement between Neogen Ionics Limited and Morita Investment Limited to produce electrolyte salt in India. It is a corporate announcement about a strategic partnership and investment, not a financial report, earnings release, or regulatory filing. The document does not contain financial statements, audit information, or voting results. It is not a report publication announcement since it is a substantive announcement itself, not merely stating that a report is attached or published. The content fits best under Capital/Financing Update (CAP) as it relates to a significant financing and joint venture agreement involving capital investment and strategic business development.
2025-11-28 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is an official announcement addressed to stock exchanges (BSE and NSE) regarding an update on a Joint Venture Agreement executed between Neogen Ionics Limited (a wholly owned subsidiary of the company) and Morita Investment Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30 and 51(2), which pertain to disclosure of material events and agreements. The content details the JV agreement terms, shareholding ratios, business scope, and strategic rationale. There is no financial statement or comprehensive financial analysis included, nor is this a full annual or interim report. The document is a regulatory announcement about a capital/financing related event (joint venture investment and capital structure). It is not a report publication announcement since the document itself contains substantive information about the JV. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-11-28 English
Arrangements for strategic, technical, manufacturing, or marketing tie up
Regulatory Filings Classification · 95% confidence The document is an official announcement addressed to stock exchanges (BSE and NSE) regarding an update on a Joint Venture Agreement executed between Neogen Ionics Limited (a wholly owned subsidiary of the company) and Morita Investment Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30 and 51(2), which pertain to disclosure of material events and agreements. The content details the JV agreement terms, shareholding ratios, business scope, and strategic rationale. There is no financial statement or comprehensive financial analysis included, nor is this a full annual or interim report. The document is a regulatory announcement about a material corporate event (joint venture agreement) and not a financial report or earnings release. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about a significant corporate transaction disclosed under listing regulations.
2025-11-28 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an official announcement addressed to stock exchanges (BSE and NSE) regarding an update on a Joint Venture Agreement between Neogen Ionics Limited (a wholly owned subsidiary) and Morita Investment Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30 and 51(2), which pertain to disclosure of material events and agreements. The content details the JV agreement terms, shareholding ratios, business scope, and strategic rationale. There is no financial statement or comprehensive financial analysis present, nor is this a report or presentation. The document is a regulatory announcement informing the market about a material business development (joint venture agreement). This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like M&A filings or capital changes. The document length (9876 characters) and detailed disclosure support this classification rather than a brief announcement or a report publication notice.
2025-11-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.